Also higher was IDM Pharmaceuticals (IDMI - Cramer's Take - Stockpickr), shares of which bounded 54 cents, or 20.5%, to $3.18. The rise came after a Cantor Fitzgerald analyst predicted the stock will quadruple over the next year after the company launches a cancer drug, according to the Associated Press. The analyst initiated coverage with a buy rating and a target share price of $11. http://www.thestreet.com/_yahoo/newsanalysis/winnershealth/10359079.html?cm_ven=YAHOO&cm_cat....